Pulmonary Arterial Hypertension - Epidemiology Forecast to 2029

Summary Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vascular proliferation and remodeling of the small pulmonary arteries (Humbert et al.

New York, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pulmonary Arterial Hypertension - Epidemiology Forecast to 2029" - https://www.reportlinker.com/p05975183/?utm_source=GNW
, 2004; Humbert et al., 2010; Simonneau et al., 2004). In PAH, blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs (Mayo Clinic, 2020). This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure (Humbert et al., 2004, 2010; Simonneau et al., 2004).

Epidemiologists utilized national databases, registries, and robust peer-reviewed journal articles to build the diagnosed incident and diagnosed prevalent cases of PAH forecast in the 7MM.epidemiologists used registry data for the forecast of diagnosed incident cases and diagnosed prevalent cases of PAH in the US and 5EU, and then adjusted them for underestimation.

For the diagnosed incident and diagnosed prevalent cases of PAH forecast for Japan, epidemiologists used data available from the Ministry of Health statistics in Japan that reflect the accurate patient population.epidemiologists kept the forecast methodology consistent across the 7MM.

The report and model include a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of PAH in the 7MM, segmented by age, sex, NYHA functional classes, and comorbidities.

The following data describes epidemiology of PAH. In the 7MM, epidemiologists forecast an increase in the diagnosed incident cases of PAH from 12,487 cases in 2019 to 12,752 cases in 2029, at an AGR of 0.21% over the forecast period. The diagnosed prevalent cases of PAH in the 7MM will increase from 67,369 cases in 2019 to 68,241 cases in 2029, at an AGR of 0.13%. PAH occurs twice as frequently in women as in men. These trends are reflected in forecast for the diagnosed incident and diagnosed prevalent cases for the 7MM.

Scope
- The Pulmonary Arterial Hypertension (PAH) Epidemiology Report provides an overview of the risk factors and global trends of PAH in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of PAH segmented by sex and age (all ages). The prevalent cases of PAH are also segmented by New York Heart Association (NYHA) functional classes (NYHA functional classes I and II, NYHA functional class III, and NYHA functional class IV), and comorbidities (connective tissue disease, scleroderma, diabetes, chronic obstructive pulmonary disease, portal hypertension, and coronary heart disease) in these markets.
- The PAH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy
The Pulmonary Arterial Hypertension Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global PAH market.
- Quantify patient populations in the global PAH market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PAH therapeutics in each of the markets covered.
- Understand magnitude of PAH population by severity at diagnosis.
Read the full report: https://www.reportlinker.com/p05975183/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001